Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting EGFR Mutations in Matched Tumor Tissue, Cell Block, Pleural Effusion and Blood of Lung Cancer Patients With Malignant Pleural Effusion

In Vivo. 2019 Mar-Apr;33(2):595-603. doi: 10.21873/invivo.11516.

Abstract

Background/aim: This study compared the efficacy of PANAMutyper™, a novel technology that integrates PNAClamp™ and PANA S-Melting™, and PNAClamp™ alone for the detection of EGFR mutations in lung cancer patients.

Materials and methods: PANAMutyper™ and PNAClamp™ were used to assess the EGFR mutation status in tissue, cell block, pleural effusion, and blood samples of 90 lung cancer patients with malignant pleural effusion.

Results: PANAMutyper™ detected more EGFR mutations than PNAClamp™, especially in body fluids (pleural effusion and serum). Patients with additional EGFR mutations detected using PANAMutyper™ had a favorable response to EGFR-tyrosine kinase inhibitor (TKI) treatment.

Conclusion: The diagnostic performance of PANAMutyper™ was superior to that of PNAClamp™ for the detection of EGFR mutations. It was also better at identifying lung cancer patients with malignant pleural effusion who were likely to benefit from EGFR-TKI treatment.

Keywords: EGFR mutation; PNA clamping; PNA clamping-assisted fluorescence melting curve analysis; lung cancer; malignant pleural effusion.

MeSH terms

  • Aged
  • DNA Mutational Analysis*
  • ErbB Receptors / genetics
  • Female
  • Freezing
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Mutation
  • Peptide Nucleic Acids / genetics
  • Pleural Effusion, Malignant / drug therapy
  • Pleural Effusion, Malignant / genetics*
  • Pleural Effusion, Malignant / pathology
  • Protein Kinase Inhibitors / administration & dosage

Substances

  • Peptide Nucleic Acids
  • Protein Kinase Inhibitors
  • EGFR protein, human
  • ErbB Receptors